Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $51
Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $57 to $51.
Stocks · News reference
Elutia Obtains $8M Payment from Boston Scientific; Co. Now Fully Funded into 2029
Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
China Adult Feeding Tubes and Formula Market Outlook to 2033 - Revenue, Volume, Pricing, and Company Share | Forecast Data Reveals Market Entry and Expansion Opportunities
ResearchAndMarkets.com released a comprehensive market report on China's adult feeding tubes and formula market through 2033, providing revenue, volume, and pricing forecasts. The report analyzes two main segments (Adult Feeding Tubes and Adult Feeding Formula) and includes competitive landscape data with 2025 company share information for key market participants.
Barclays Initiates Coverage On Boston Scientific with Equal-Weight Rating, Announces Price Target of $48
Barclays analyst Christopher Pasquale initiates coverage on Boston Scientific (NYSE:BSX) with a Equal-Weight rating and announces Price Target of $48.
8-K filing — BOSTON SCIENTIFIC CORP (BSX)
Filed: 2026-10-07 AccNo: 0000885725-26-000064 Size: 292 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
8-K filing — ELUTIA INC. (ELUT)
Filed: 2026-08-21 AccNo: 0001104659-26-099731 Size: 644 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Elutia Q2 2026 Earnings Call Transcript
On Thursday, Elutia (NASDAQ:ELUT) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to